# Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.

> **NCT00170911** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 160 (—)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** AAE581

## Key facts

- **NCT ID:** NCT00170911
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2005-12
- **Final completion:** —
- **Target enrollment:** 160 (—)
- **Last updated:** 2011-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170911, "Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00170911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*